Fundación para la Gestión de la Investigación Biomédica de Cádiz

Their core work

FGIBICA is a biomedical research management foundation based in Cádiz, Spain, that supports and conducts clinical and translational research — primarily in paediatric neurology, neonatal medicine, and infectious disease. Their work bridges hospital clinical practice and structured research programmes, applying tools like neuroimaging, eye-tracking, and AI-assisted biomarkers to improve early diagnosis of conditions in premature and high-risk newborns. In parallel, they contribute to public health research addressing antimicrobial resistance and infection control in clinical settings. As a foundation rather than a university, they act as a legal and operational vehicle for research conducted within regional healthcare institutions.

What they specialise in

How they've shifted over time

FGIBICA's H2020 activity began (2020) with a focused specialisation in neonatal neurology — specifically early-detection tools for premature infants facing cerebral palsy or cognitive impairment, integrating neuroimaging, eye-tracking, and AI. By 2021, their second project marks a pivot toward antimicrobial resistance and hospital infection management — a distinct clinical domain with different methods (epidemiological and health-economic rather than imaging-based). With only two projects spanning just one year apart, it is difficult to call this a clear strategic shift; it may reflect opportunistic participation or internal clinical breadth rather than a deliberate programmatic change.

FGIBICA appears to be broadening from a neonatal neurodevelopment niche toward general clinical research infrastructure, suggesting they may be an attractive third-party clinical site for health projects requiring hospital-based recruitment or validation in southern Spain.

How they like to work

FGIBICA has never coordinated an H2020 project — they participate as a partner or third party, consistent with the role of a regional biomedical foundation that provides clinical access and research management support rather than scientific leadership. Their involvement in a 25-partner consortium (PARENT) suggests comfort working within large, multi-country networks. As a third party in REVERSE, they likely contribute patient data, clinical validation capacity, or local implementation rather than methodology design.

FGIBICA has connected with 25 unique consortium partners across 10 countries through just two projects — an unusually broad network relative to their project volume. This suggests they joined well-connected consortia rather than building a personal collaborative network over time.

What sets them apart

FGIBICA occupies a specific niche as a hospital-affiliated biomedical research foundation in southern Spain — a region underrepresented in EU research consortia — which gives them geographic and clinical access value for projects needing Spanish patient cohorts or clinical validation sites. Their dual exposure to neonatal intensive care research and antimicrobial resistance makes them relevant for health projects that bridge paediatrics and infectious disease. For consortium builders, they offer administrative and ethical research management infrastructure anchored in a regional healthcare system.

Highlights from their portfolio

• PARENT
  Their only funded project (€501,810), combining AI, neuroimaging, and eye-tracking for early diagnosis of cerebral palsy in premature newborns — a technically complex and clinically impactful scope for a regional foundation.
• REVERSE
  Participation as a third party in a large RIA on antibiotic resistance signals a deliberate expansion into infectious disease and health economics, distinct from their neonatal neurology origins.